x
By RTTNews Staff Writer | Published: 10/30/2020 10:40 AM ET
Image by Gerd Altmann from Pixabay
Shares of Equillium, Inc. (EQ) are gaining more than 14 percent or $0.86 in Friday's morning trade at $6.86.
Thursday, Equillium said it has received FDA clearance to commence a phase III clinical trial of Itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome or ARDS. The company plans to begin patient enrollment in the trial named EQUINOX in the fourth quarter, with initial clinical data expected mid-year 2021.
Equillium has traded in a range of $2.20 to $27.05 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Markethive Advertisement
Article written by an RTT News Staff Writer, and posted on the RTT News.com website.
Article reposted on Markethive by Jeffrey Sloe
